1800 103 7100
info@mohanfoundation.org
MOHAN Foundation

Menu

Skip to content
  • About
  • Free Downloads
  • Videos

No hay riesgos por Rituximab – Comunicado-Prensa.com (Comunicado de prensa)

February 5, 2013Monoclonal Anti-CD20 Antibodiesadmin

No hay riesgos por Rituximab
Comunicado-Prensa.com (Comunicado de prensa)
Hasta la fecha no hay ningún reporte confirmado del riesgo de efectos adversos graves de Rituximab ni muertes asociadas al tratamiento con este medicamento. Así lo confirma un comunicado del Laboratorio Roche, que comercializa Rituximab en ...

Post navigation

← Substandard drugs blamed for TB crisis – Aljazeera.com Cells Predict Onset of Graft-Versus-Host Disease in Men Receiving Bone … – Science Daily (press release) →

Categories

  • Antibodies
  • Blood donation
  • Bone marrow donation and transplantation
  • Brain Death Declaration
  • Chronic Allograft Nephropathy
  • Donor Card
  • Drugs/Medicine
  • Google News RSS feed URL deprecation
  • Heart
  • HLA Typing
  • Immunosuppressive Drugs
  • Infectious Disease
  • Intestinal
  • Islet
  • Kidney
  • Liver
  • Lung
  • Monoclonal Anti-CD20 Antibodies
  • Monoclonal Anti-IL-2Rα Receptor Antibodies
  • Nephrology
  • Organ Donation
  • Organ Donor
  • Organ Failure
  • Organ Preservation Methods
  • Organ Preservation Solution
  • Organs
  • Other Transplantation
  • Pancreas
  • Pharma News
  • Polyclonal Anti-T-Cell Antibodies
  • Tissue Donation
  • Transplant laws
  • Transplant Rejection
  • Transplant Studies
  • Transplant Surgery
  • Transplant Tourism
  • Transplant Trials
  • Transplantation
  • Uncategorized
Copyright © MOHAN Foundation
Powered by WordPress , Theme i-excel by TemplatesNext.
MENU
    • About
    • Free Downloads
    • Videos